Ceftolozane-tazobactam combo new treatment of gram-negative bacterial infections: Study
Many in vitro studies have previously shown that a novel combination of Ceftolozane-tazobactam exhibits potent activity against most clinically important gram-negative bacteria, including multidrug-resistant (MDR) bacteria. Clinically, ceftolozane-tazobactam has also shown favorable efficacy for the treatment of complicated intra-abdominal infection and uncomplicated/complicated urinary tract infection (cUTI).
A recent study, published in Therapeutic Advances in Drug Safety, has suggested that Ceftolozane-tazobactam treatment is as tolerable as comparative treatment options for acute bacterial infections in adult patients, however it has an increased risk of C. difficile infection. The study has further elaborated that as a novel broad-spectrum antibiotic, ceftolozane-tazobactam could be a safe therapeutic option for use in common clinical practice.
The aim of this current study was to conduct a meta-analysis to assess the clinical safety of ceftolozane-tazobactam for the treatment of acute bacterial infections in adult patients.
The study design consisted of PubMed, Embase, and Cochrane databases, which were searched from their inception until May 2020 for relevant randomized controlled trials (RCTs). Only RCTs evaluating the risk of adverse events (AEs) for ceftolozane-tazobactam and comparative treatments for acute bacterial infections in adult patients were included.
Results revealed some interesting facts.
- Overall, four RCTs including a total of 2924 patients (1475 in the ceftolozane-tazobactam group and 1449 in the control group) were included in the meta-analysis.
- The rate of treatment-emergent AEs was 51.3% (748/1458) in the ceftolozane-tazobactam group, which was comparable to the control group, 49.9% [714/1430; odd's ratio (OR), 1.06; 95% confidence interval (CI), 0.91–1.25; I2 = 0%].
- In addition, no difference was observed between the ceftolozane-tazobactam and control groups in terms of the risk of serious AEs (OR, 1.22; 95% CI, 0.93–1.61; I2 = 15.5%) and the risk of discontinuing the study drug due to AEs (OR, 0.85; 95% CI, 0.55–1.33; I2 = 0%).
- The rate of all-cause mortality did not significantly differ between the ceftolozane-tazobactam and control groups (OR, 1.11; 95% CI, 0.82–1.50; I2 = 0%).
- The only exception was the risk of Clostridiodes difficile (C. difficile) colitis, where ceftolozane-tazobactam treatment was associated with a significantly higher risk compared with the control group [0.72% (10/1376) versus 0.14% (2/1391), OR, 3.84; 95% CI, 1.23–11.97; I2 = 0%].
"This meta-analysis of four RCTs demonstrated that the safety of ceftolozane-tazobactam is comparable to that of alternative treatment options for patients with acute bacterial infections." the team concluded.
For full article follow the link: https://doi.org/10.1177%2F20420986211027096
Source: Therapeutic Advances in Drug Safety
